 we report on our first quarter 2022 financial results and provide an update on our preclinical programs in the hepatitis b and coronavirus space. 
 we also discuss the status of the 2 combination studies with 729 and 836 that we expect to report in the second half of 2022.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 